MacDougall Biomedical Communications represents Cambridge-based Momenta Pharmaceuticals as it agrees to be acquired by Johnson & Johnson for $6.5B cash.
It's the biggest pharmaceuticals deal of the year, according to Bloomberg, and the latest sign that drug companies are "looking for ways to bulk up even as the coronavirus pandemic upends other businesses."
Craig Wheeler, CEO of Momenta, called J&J the right company to advance its portfolio of drug candidates for autoimmune and rare diseases.
"J&J’s leadership in immunology, extensive capabilities, and global reach, as well as its alignment with our vision of pioneering therapies for complex diseases, is a strong fit for our company and our portfolio,” he said.
The deal will be completed by the end of the year
MacDougall Biomedical managing director Karen Sharma, a veteran of Schwartz Communications and Newgrange Consulting, represents Momenta.